U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07938294) titled 'Sotatercept in the Treatment of Methamphetamine-Associated Pulmonary Arterial Hypertension' on Aug. 06.

Brief Summary: The goal of this clinical trial is to find out whether sotatercept, an FDA-approved medication for people with pulmonary arterial hypertension (PAH), can improve health outcomes for people with PAH due to use of methamphetamine. The main question it aims to answer is whether sotatercept added to standard background therapy and addiction medicine services will improve treatment response as measured by:

* Echocardiographic measurements of pulmonary hypertension

* Change in 6-minute walk distance (6MWD)

* Change in ...